Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BHVN (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 86.23% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.31B USD | Price to earnings Ratio - | 1Y Target Price 63.47 |
Price to earnings Ratio - | 1Y Target Price 63.47 | ||
Volume (30-day avg) 1151490 | Beta 3.91 | 52 Weeks Range 21.47 - 55.72 | Updated Date 04/2/2025 |
52 Weeks Range 21.47 - 55.72 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.28 |
Earnings Date
Report Date 2025-03-03 | When - | Estimate -1.4712 | Actual -1.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -96.85% | Return on Equity (TTM) -198.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1857261977 | Price to Sales(TTM) - |
Enterprise Value 1857261977 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 102065000 | Shares Floating 84647063 |
Shares Outstanding 102065000 | Shares Floating 84647063 | ||
Percent Insiders 11.97 | Percent Institutions 91.81 |
Analyst Ratings
Rating 4.67 | Target Price 65.29 | Buy 5 | Strong Buy 10 |
Buy 5 | Strong Buy 10 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biohaven Pharmaceutical Holding Co Ltd
Company Overview
History and Background
Biohaven Pharmaceutical was founded in 2013 and focused on developing innovative therapies for neurological and neuropsychiatric diseases. Its major milestone was the FDA approval of Nurtec ODT for migraine, which led to its acquisition by Pfizer in 2022.
Core Business Areas
- Migraine Treatment: Focuses on Nurtec ODT (rimegepant), an oral CGRP receptor antagonist for the acute and preventive treatment of migraine.
- Neurodegenerative Diseases (Pre-acquisition): Prior to being acquired by Pfizer the company researched therapies for diseases such as Spinocerebellar Ataxia (SCA) and Amyotrophic Lateral Sclerosis (ALS).
Leadership and Structure
After Pfizer's acquisition, Biohaven as a standalone entity ceased to exist. The migraine portfolio and other select assets were integrated into Pfizer. The remaining research assets were spun out into a new entity, Biohaven Labs, which operates independently.
Top Products and Market Share
Key Offerings
- Nurtec ODT (Rimegepant): An oral CGRP receptor antagonist for the acute and preventive treatment of migraine. Market share data is dynamic and fluctuates, now under Pfizer's management. Competitors include other CGRP inhibitors from Amgen (Aimovig), Eli Lilly (Emgality), Teva (Ajovy), and oral options like Ubrelvy (ubrogepant) from AbbVie.
Market Dynamics
Industry Overview
The migraine treatment market is highly competitive and growing, driven by increased awareness and the availability of novel therapies such as CGRP inhibitors. The overall pharma market is constantly shifting due to patents ending and also new therapies in development and production.
Positioning
Biohaven, before acquisition, was a leader in oral CGRP inhibitors with Nurtec ODT. Pfizer now holds this position. Pfizer has competitive advantages and is positioned for further growth within that market.
Total Addressable Market (TAM)
The global migraine therapeutics market is estimated to be worth billions of dollars. Biohaven, through Nurtec ODT now owned by Pfizer, captured a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Innovative oral CGRP inhibitor (Nurtec ODT)
- Experienced management team (pre-acquisition)
- Strong research and development pipeline (pre-acquisition)
Weaknesses
- Dependence on a single key product (Nurtec ODT)
- Intense competition in the migraine market
- Regulatory and clinical trial risks
Opportunities
- Expanding Nurtec ODT's market share
- Developing new therapies for other neurological disorders (Biohaven Labs)
- Potential acquisitions and partnerships (Biohaven Labs)
Threats
- Generic competition
- Pricing pressures from payers
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- PFE
- ABBV
- LLY
- AMGN
- TEVA
Competitive Landscape
The market is very competitive. Pfizer has the advantage of Nurtec ODT, Abbvie with Ubrelvy, Eli Lilly with Emgality, Amgen with Aimovig, and Teva with Ajovy.
Major Acquisitions
Biohaven Pharmaceutical by Pfizer
- Year: 2022
- Acquisition Price (USD millions): 11600
- Strategic Rationale: Pfizer acquired Biohaven to expand its neuroscience portfolio, specifically gaining access to Nurtec ODT.
Growth Trajectory and Initiatives
Historical Growth: Biohaven experienced rapid growth in revenue following the launch of Nurtec ODT.
Future Projections: Future growth is split. Nurtec ODT's growth depends on Pfizer. Other neurological disorder therapies depend on Biohaven Labs.
Recent Initiatives: Biohaven Labs continues to research treatment for Spinocerebellar Ataxia (SCA) and Amyotrophic Lateral Sclerosis (ALS).
Summary
Biohaven Pharmaceutical was a successful company driven by Nurtec ODT, and it was strategically acquired by Pfizer to enhance its portfolio. Biohaven Labs could discover a future drug for different ailments in the field of neuroscience. Pfizer needs to continue growing Nurtec's market share to maintain its leadership position in the migraine treatment market. They also need to beware of generic competition in the future.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
AMGN
Amgen Inc
AMGN
Amgen Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
PFE
Pfizer Inc
PFE
Pfizer Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biohaven Pharmaceutical Holding Co Ltd
Exchange NYSE | Headquaters New Haven, CT, United States | ||
IPO Launch date 2022-09-23 | Chairman & CEO Dr. Vladimir Coric M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 256 | Website https://www.biohaven.com |
Full time employees 256 | Website https://www.biohaven.com | ||
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.